Observational Study of Afatinib 30 mg Daily

NCT04909073 · clinicaltrials.gov ↗

RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Epidermal Growth Factor Receptor Mutation

Interventions

DRUG: Afatinib

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]